- The Amgen Golden Ticket Award, now in its third year,
showcases Amgen's and NSG BioLabs' efforts to support high-growth
startups in a nurturing ecosystem, with a doubling of applicants
compared to last year
- Amgen and NSG BioLabs extended the Golden Ticket partnership
for another three years demonstrating continued commitment
to advancing Singapore's biotech
sector
- This year's winner, PairX Bio, will receive valuable access
to mentorship from Amgen's thought leaders and a year-long
residency at NSG BioLabs, a space meticulously designed for
scientists
- NSG BioLabs has also partnered with CapitaLand to establish
its fourth site, bringing its total size to 70,000 square feet, set
to be Southeast Asia's largest
co-working laboratory space
SINGAPORE, July 17,
2024 /PRNewswire/ -- Leading global biotechnology
company Amgen, and NSG BioLabs, Singapore's largest provider of biotech
co-working biosafety level 2 laboratories, celebrate the successful
conclusion of their third annual Amgen Golden Ticket competition
today. This year marked a significant milestone with a doubling of
applicants compared to last year, reflecting burgeoning interest in
the industry and the vibrancy of Singapore's biotech ecosystem. Collaborative
initiatives, such as the Amgen Golden Ticket, exemplify the
commitment of industry leaders like Amgen and NSG BioLabs to
advancing Singapore's biotech
landscape and supporting innovative and high-growth startups.
Building on the success of the awards programme, Amgen and NSG
BioLabs are pleased to announce the extension of the Amgen Golden
Ticket Programme for another three years.
![PairX Bio named winner of the Amgen x NSG BioLabs Golden Ticket Awards 2024. (PRNewsfoto/NSG BioLabs) PairX Bio named winner of the Amgen x NSG BioLabs Golden Ticket Awards 2024. (PRNewsfoto/NSG BioLabs)](https://mma.prnewswire.com/media/2464195/AMGEN_24.jpg)
This year, PairX Bio, a pre-clinical stage biotech company that
pairs novel biology-based cancer targets with optimal therapeutic
modalities to revolutionise cancer-selective biologics, was awarded
the Amgen Golden Ticket. This entitles them to invaluable
mentorship opportunities within Amgen's expansive network of
scientific and business leaders. PairX Bio will also benefit from a
year-long residency at NSG BioLabs' fully-equipped lab space
designed with scientists in mind.
"We are thrilled to witness the growing impact of the Amgen
Golden Ticket Programme over the past three years in Singapore. Like other successful Golden Ticket
initiatives sponsored by Amgen around the world, this programme has
been pivotal in fostering innovation and supporting promising
companies such as PairX Bio. Their breakthrough research in
oncology holds the potential to drive impactful advancements in
patient care in the future. We take pride in contributing to the
biotech sector in Singapore and
remain committed to nurturing the next generation of biotech
leaders with our extended commitment through
2027," said Dr. Alan
Russell, Vice President, Biologics Therapeutic Discovery,
Amgen.
"We are deeply honoured to receive Amgen's prestigious Golden
Ticket Award. This recognition validates the groundbreaking work of
our team to develop next-generation cancer-selective biologics. We
are grateful for Amgen's support and proud to be part of the
vibrant life sciences ecosystem in Singapore, where collaboration and innovation
are driving significant advancements in healthcare. We look forward
to leveraging this opportunity to further our mission of
transforming cancer treatment and improving patient outcomes,"
said David M. Epstein,
Co-founder, CEO and President, PairX Bio.
The accolade follows in the footsteps of past recipients like
Albatroz Therapeutics, a pre-clinical stage biotech company that
develops therapeutic antibodies to treat solid tumors, and
VerImmune, an immuno-oncology company focused on redirecting
pre-existing immune memory from past infections or childhood
vaccines to target cancer. Both winners benefited from
the mentorship and access to industry that helped them
accelerate their research and development efforts. Albatroz raised
their seed funding round of US$3
million in early 2023i while VerImmune
raised US$3.1 million in
2023ii following an initial US$2.5 million raise in 2022, and achieved
milestones such as a successful FDA pre-IND
meetingiii.
"NSG BioLabs empowers biotech startups by providing top-tier
BSL-2 laboratory spaces, offering scientists a conducive
environment to conduct their research, and bring their ideas to
fruition. By fostering connections between leading pharmaceutical
companies and pioneering startups, we cultivate collaboration that
drives healthcare advancements. We deeply appreciate our strong
partnership with the Amgen team and look forward to future
collaborations with other industry leaders. Together, we are
dedicated to advancing Singapore's
biotech sector, fostering an environment where ideas thrive and
transformative innovations flourish," said Daphne Teo, CEO and Founder, NSG
BioLabs.
NSG BioLabs Partners with CapitaLand on its Fourth Facility
at Geneo in Singapore Science Park
to Create Southeast Asia's Largest Co-working
Laboratory
Hot on the heels of the successful conclusion of its third
annual Amgen Golden Ticket competition, NSG BioLabs is joining
forces with CapitaLand to launch a new innovation hub at the Geneo
life sciences and innovation cluster in Singapore Science Park. Combining CapitaLand's
real estate expertise with NSG BioLabs' deep experience and
networks in the biotech ecosystem, this collaboration will create
Southeast Asia's largest
co-working laboratory space at approximately 35,000 square
feet.
The state-of-the-art hub will feature shared wet labs, flexible
workspaces, and a well-equipped meeting and conference venue,
catering to the R&D and collaboration needs of life science and
deep tech companies. This dynamic hub aims to empower enterprises
of all sizes to foster collaborative innovation, leading to
groundbreaking discoveries and scaled ventures. This expansion will
also bring NSG BioLab's total size to more than 70,000 square feet,
making it the largest co-working biotech lab in Southeast Asia.
"CapitaLand's partnership with NSG BioLabs marks an exciting
new development for Geneo at Singapore Science Park as we introduce
the biotech co-working lab space to support the growth and
development of the life sciences and deep tech companies in
Singapore. From developing
pioneering products to fostering industry engagements, Geneo is set
to become a key driver of innovation and collaboration in
Singapore's thriving life sciences
and deep tech sectors," said Mr. Chew Peet Mun, Managing Director, Investment and
Development, CapitaLand Development Singapore.
With rising healthcare burdens and evolving pandemics, the need
for stronger collaboration within the ecosystem has become
increasingly critical to discover solutions that can make an impact
on society. NSG BioLabs is excited to continue partnering with
industry leaders like Amgen and CapitaLand in joint missions to
support the growing biotech ecosystem.
The upcoming co-working laboratory innovation hub is one of the
key features of Geneo, which comprises three properties with five
state-of-the-art buildings that will offer about 1.94 million sq ft
of gross floor area with work-live-play elements when fully
completed in 2025. Geneo is jointly developed by CapitaLand
Development and CapitaLand Ascendas REIT.
About Amgen
Amgen harnesses the best of biology and technology to fight the
world's toughest diseases, and make people's lives easier, fuller
and longer. We helped establish the biotechnology industry, and we
remain on the cutting-edge of innovation, using technology and
human genetic data to push beyond what's known today. Our
investment in research and development has yielded a robust
pipeline that builds on our existing portfolio of medicines to
treat cancer, heart disease, osteoporosis, inflammatory diseases
and rare diseases.
Amgen is one of 30 companies comprising the Dow Jones Industrial
Average®, and part of the Nasdaq-100 Index®.
In 2024, Amgen was named one of the "World's Most Innovative
Companies" by Fast Company and one of "America's Best Large
Employers" by Forbes.
For more information, visit Amgen.com and follow us on X,
LinkedIn, Instagram, TikTok, YouTube and Threads.
About NSG BioLabs
Founded with a focus on supporting biotech innovation, NSG
BioLabs offers state-of-the-art equipment, efficient operations,
capital efficiency, the expertise of world-class teams and global
networks to assist life sciences companies. The conducive R&D
environment contains fully-equipped, certified BSL-2 laboratory and
office infrastructure across 70,000 sq ft within Singapore's biomedical science clusters,
Biopolis and Singapore Science Park.
By providing access to high-quality infrastructure, its
extensive partner network, community, and value-add benefits, NSG
BioLabs ensures that companies, ranging from emerging biotech
startups to multinational companies, can rapidly and efficiently
execute on their cutting-edge research and development ecosystem
in Singapore, leading to the innovation of revolutionary
technologies and products that translate into breakthrough biotech
ventures and impact for patients. For more information,
visit www.nsgbio.com
About PairX Bio
PairX Bio is pioneering the development of next-generation
cancer-selective biologics by identifying novel, highly prevalent,
tumor-selective cell surface variants. Our biology-driven approach
reveals a new class of therapeutic targets that can be paired with
a variety of optimal therapeutic modalities. Founded on IP
exclusively licensed from Duke-NUS Medical School, Singapore, PairX Bio is advancing a robust
pipeline of potential first- and best-in-class tumor-selective
therapies targeting prevalent cancers in substantial patient
populations. PairX Bio is backed by top-tier investors with
Seed financing led by Versant Ventures.
For more information,
visit www.PairXbio.com and find us on
LinkedIn.
About CapitaLand Group (www.capitaland.com)
CapitaLand Group (CapitaLand) is one of Asia's largest diversified real estate groups.
Headquartered in Singapore,
CapitaLand's portfolio focuses on real estate investment management
and real estate development, and spans across more than 260 cities
in over 40 countries.
Within its ecosystem, CapitaLand has developed an integrated
suite of investment management and operating capabilities that
supports its real estate businesses and platforms in building core
competencies across the real estate value chain. With this full
stack of capabilities, CapitaLand can optimise the strategies of
its listed real estate investment management business CapitaLand
Investment, and its privately held property development arm
CapitaLand Development; to drive competitive advantage for its
businesses.
CapitaLand places sustainability at the core of what it does. As
a responsible real estate company, CapitaLand contributes to the
environmental and social well-being of the communities where it
operates, as it delivers long-term economic value to its
stakeholders.
Follow @CapitaLand on social media
Facebook: @capitaland / facebook.com/capitaland
Instagram: @capitaland / instagram.com/capitaland
Twitter: @capitaLand / twitter.com/capitaland
LinkedIn: linkedin.com/company/capitaland-limited
YouTube: youtube.com/capitaland
i
https://www.albatroztherapeutics.com/news/albatroz-therapeutics-secure-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation/
|
ii
https://www.verimmune.com/news/verimmune-inc-announces-over-3m-additional-funding
|
iii
https://www.verimmune.com/news/verimmune-announces-positive-pre-ind-meeting-with-fda
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pairx-bio-clinches-coveted-amgen-golden-ticket-award-as-nsg-biolabs-deepens-efforts-with-partners-capitaland-and-amgen-to-boost-singapores-biotech-ecosystem-with-fourth-site-and-extended-awards-programme-302200193.html
SOURCE NSG BioLabs